Summary of Key Points from Conference Call Records Industry Overview - **Banking Sector Stability**: The banking sector is experiencing a stable fundamental environment due to local government debt resolution and fiscal injections, which are gradually alleviating risks in real estate and city investment. This has led to capital replenishment for banks, with improved interest margins as regulatory measures have lowered deposit rates, particularly benefiting small banks and stabilizing large banks' margins [1][2][5]. Core Insights and Arguments - **Stock Performance and Valuation Recovery**: Since May 2025, the banking sector has seen accelerated stock price increases, driven by high dividend yields and passive index fund investments. Active funds have begun increasing their positions in bank stocks, which is expected to continue for one to two years, particularly benefiting high-quality city commercial banks that may exceed a price-to-book (PB) ratio of 1.0 [1][2][5][6]. - **Potential for Valuation Recovery in Leading City Commercial Banks**: Leading city commercial banks such as Hangzhou Bank, Jiangsu Bank, and Chengdu Bank are projected to have dividend yields exceeding 4%, supported by strong asset quality primarily from government-related businesses. This positions them well for valuation recovery beyond a PB of 1.0 [1][4][6]. - **Future Trends in Banking**: The regulatory support for systemically important financial institutions is underestimated, leading to better-than-expected fundamentals in the banking sector. The focus of stock selection is shifting from low valuation to high return on equity (ROE), high growth rates, and long-term regional advantages [1][5]. - **Market Recognition of Bank Stocks**: There is a growing market recognition of bank stocks, reflected in trading activity and initial valuation increases. The expectation is that leading city commercial banks could see their asset valuations recover to 1.2 times PB [6]. Additional Important Insights - **Investment Strategy in Real Estate**: The focus in the real estate sector is on stable cash flow and potential high dividend yield companies, including comprehensive developers and pure commercial real estate firms. The emphasis is on dividend rates, free cash flow stability, and the quality of non-self-owned business assets [3][7][9]. - **Selection Logic for Light Asset Companies**: The selection criteria for light asset companies include static dividend yields between 5% and 10%, growth potential, and the pricing of excess cash. Companies with strong free cash flow relative to market capitalization are prioritized [3][12][13]. - **Market Environment and Investment Focus**: In the current uncertain market environment, there is a heightened interest in assets with stable cash flows and improving dividend capabilities. These assets are considered scarce and are expected to attract more investor attention [14]. - **Impact of Stablecoin Developments**: The recent approval of a stablecoin scheme in Hong Kong is anticipated to increase demand for local currency stablecoins, particularly as the market for stablecoins continues to grow in Asia and Europe [15][16]. This summary encapsulates the key points from the conference call records, highlighting the banking sector's stability, valuation recovery potential, and strategic investment insights across various sectors.

证券研究报告·行业跟踪周报·建筑材料 建筑材料行业跟踪周报 家庭消费仍有潜力，期待服务消费刺激 2025 年 06 月 08 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 黄诗涛 执业证书：S0600521120004 huangshitao@dwzq.com.cn 证券分析师 房大磊 执业证书：S0600522100001 fangdl@dwzq.com.cn 证券分析师 石峰源 执业证书：S0600521120001 shify@dwzq.com.cn 行业走势 -20% -16% -12% -8% -4% 0% 4% 8% 12% 16% 2024/6/11 2024/10/9 2025/2/6 2025/6/6 建筑材料 沪深300 相关研究 《建筑业 PMI 底部区间波动，推荐消 费建材》 2025-06-03 《继续推荐消费建材》 2025-05-25 东吴证券研究所 1 / 20 请务必阅读正文之后的免责声明部分 ◼ 本周（2025.6.3–2025.6.6，下同）：本周建筑材料板块（SW）涨跌幅 0.63%， 同期沪深 300、万得全 A 指数 ...

Market Performance - The Hong Kong stock market has shown strong performance this year, with the total scale of Hong Kong-themed ETFs approaching 360 billion yuan, an increase of approximately 96.1 billion yuan compared to the end of last year [1][3] - The Hang Seng Index and the Hang Seng Tech Index have increased by 18.61% and 18.32% respectively [3] ETF Growth - As of June 6, there are 144 Hong Kong-themed ETFs with a total scale of 357.24 billion yuan, up from 261.1 billion yuan at the end of last year, marking a growth of 96.1 billion yuan [3] - The largest Hong Kong-themed ETF is the FTSE China Hong Kong Internet ETF, with a scale of approximately 45.6 billion yuan [3] Fund Inflows - Southbound capital has seen a cumulative net inflow of over 600 billion HKD, accounting for nearly 82% of the expected total for 2024, with an average daily net inflow exceeding 8 billion HKD [3] - The number of Hong Kong-themed funds issued this year has reached 43, most of which are passive index funds [4] Investment Outlook - Industry experts believe that the Hong Kong stock market still holds long-term investment value, particularly in sectors such as internet, innovative pharmaceuticals, smart vehicles, and new consumption [1][4] - Despite recent gains, the valuation of Hong Kong stocks remains relatively low, with the Hang Seng Index trading at a P/E ratio of approximately 10.2, lower than the S&P 500 and CSI 300 indices [6] Sector Focus - Key investment opportunities are identified in new consumption sectors such as trendy toys, tea drinks, and domestic beauty products, as well as in technology and innovative pharmaceuticals [6][7] - The innovative pharmaceutical sector has seen overseas licensing transactions exceed 50 billion USD, indicating a potential profitability turning point [7] Market Strategy - Investors are advised to avoid chasing high prices and to focus on the fundamentals of companies, as well as changes in the macroeconomic environment [1][7] - A balanced strategy of "high dividend + technology growth" is suggested to capture both valuation recovery and industrial upgrades [6]

Quantitative Factors and Construction 1. Factor Name: Valuation Deviation (EPD) Factor - **Construction Idea**: The EPD factor is constructed by combining the mean-reversion strategy commonly used in the CTA domain with the valuation repair logic based on fundamentals. It leverages the mean-reversion characteristics of the PE valuation metric[7][2] - **Construction Process**: 1. Identify the mean-reversion property of the PE ratio as the core valuation metric 2. Construct the EPD factor to capture valuation deviations based on this mean-reversion logic[7][2] - **Evaluation**: The factor effectively captures valuation deviations and demonstrates strong performance in backtesting[7] 2. Factor Name: Slow Deviation (EPDS) Factor - **Construction Idea**: The EPDS factor is derived from the EPD factor by removing the probability of changes in individual stock valuation logic, which is proxied by the stock's information ratio[7][2] - **Construction Process**: 1. Start with the EPD factor 2. Use the information ratio of individual stocks to filter out those with altered valuation logic 3. Construct the EPDS factor to focus on slow valuation deviations[7][2] - **Evaluation**: The factor further refines the valuation deviation logic and improves performance metrics compared to the EPD factor[7] 3. Factor Name: Valuation Anomaly (EPA) Factor - **Construction Idea**: The EPA factor is constructed by further refining the EPDS factor. It removes the influence of beta, growth, and value styles to isolate the "valuation anomaly" logic[7][2] - **Construction Process**: 1. Start with the EPDS factor 2. Remove the impact of beta, growth, and value styles 3. Construct the EPA factor to focus solely on valuation anomalies[7][2] - **Evaluation**: The EPA factor demonstrates the highest performance among the three factors, with strong backtesting results and robustness[7] --- Factor Backtesting Results 1. Valuation Deviation (EPD) Factor - Annualized Return: 17.52%[2][8][12] - Annualized Volatility: 10.00%[2][8][12] - IR: 1.75[2][8][12] - Monthly Win Rate: 70.65%[2][8][12] - Maximum Drawdown: 8.93%[2][8][12] 2. Slow Deviation (EPDS) Factor - Annualized Return: 16.25%[2][8][12] - Annualized Volatility: 5.72%[2][8][12] - IR: 2.84[2][8][12] - Monthly Win Rate: 78.80%[2][8][12] - Maximum Drawdown: 3.10%[2][8][12] 3. Valuation Anomaly (EPA) Factor - Annualized Return: 17.23%[2][8][12] - Annualized Volatility: 5.11%[2][8][12] - IR: 3.37[2][8][12] - Monthly Win Rate: 80.98%[2][8][12] - Maximum Drawdown: 3.12%[2][8][12] --- Additional Insights - In May 2025, the EPA factor's 5-group long portfolio achieved a return of 3.88%, while the short portfolio returned 3.27%, resulting in a long-short spread of 0.61%[2][15] - The EPA factor's monthly RankIC mean during the backtesting period (2010/01–2022/05) was 0.061, with a RankICIR of 4.75[2][7] - The EPA factor's 5-group long-short portfolio achieved an annualized return of 18.29%, an IR of 3.76, a win rate of 86.99%, and a maximum drawdown of 1.53% during the backtesting period[7]

Group 1 - The A-share steel sector is experiencing overall weakness, with multiple companies seeing stock price declines, including Benxi Steel down 6.27% and Maanshan Iron & Steel down 4.09% [1] - Since May 19, U.S. steel stocks have cumulatively risen by 32.66% over 10 trading days, influenced by President Trump's announcement to increase import tariffs on steel from 25% to 50% [1] - Domestic steel prices in China have shown a downward trend this year, with the comprehensive steel price index dropping from 96.98 at the beginning of January to 90.8 by the end of May, a decline of over 6% [1] Group 2 - Short-term impacts of U.S. tariffs may lead to increased overseas steel prices, putting pressure on China's steel market, while medium-term price trends will depend on supply and demand dynamics [2] - The steel sector may present structural opportunities due to policy-driven industry consolidation, accelerated green transformation, increased concentration of leading companies, and valuation recovery [2] - The increase in tariffs could heighten market expectations of weakened steel demand, with potential for further price declines in the short term following the Dragon Boat Festival [2]

Summary of the Conference Call Industry Overview - The focus is on the **controller sector** and its recovery potential, particularly in the context of **laser radar and robotics** industries [1][2]. Key Points 1. The controller sector has experienced significant overselling, with a notable improvement in the underlying fundamentals, indicating potential for both performance and valuation recovery [1][2]. 2. Historical analysis over the past decade shows that the stock performance of representative companies in the controller sector, such as **He Tai** and **Tuo Bang**, is highly sensitive to earnings and raw material price fluctuations [1][2]. 3. External factors have impacted the sector, but Q1 earnings have begun to show signs of recovery [1][2]. 4. The stock price elasticity is high under thematic catalysts, suggesting potential for significant price movements [1][2]. Company-Specific Insights - **He Sai Technology**: Reported a delivery volume of nearly **200,000 units** in Q1, representing a year-on-year increase of **231%** [1][2]. - **Su Teng Ju Chuang**: Continues to narrow its net losses, with promising orders in the broader robotics sector [1][2]. Additional Important Information - The laser radar segment is identified as a "second growth curve" for the robotics field, particularly in consumer-grade robotics, indicating a shift in market dynamics and potential growth opportunities [1][2].

反正，其次是估值优势吸引外资回流呢。目前，上证50的市盈率仅为9.8倍，有23%的股票处于破净状 态；而创业板的市盈率也已经降至历史5%分位的低位。这样的估值优势使得A股市场成为全球的价值 洼地，对外资具有较大的吸引力。 展望2025年呢，市场面临着一些特殊的压力和挑战。外部方面，特朗普宣布从6月1日起提高进口钢铁税 至50%，同时美国财长也表示中美贸易谈判已经停止，这可能对出口相关行业如光伏、机械等造成打 击。此外，美联储降息的时间推迟到12月，美债收益率上升，使得全球投资者变得更加谨慎。内部方 面，5月31日的股市交易额创下今年新低，仅为7150亿元，表明市场观望情绪浓厚。如果假期后交易额 不能恢复到万亿水平，反弹的机会可能会减小。 然而呢，要打破这一僵局，有三个关键力量值得关注。首先是政策支持和流动性的改善。央行降准释放 了1.2万亿的流动性，地方债的置换速度加快，银行的利息差也有所提高。这为金融股的估值修复提供 了空间，如市净率仅0.6倍的国有银行。此外，长期资金也在持续进场，保险公司每年增加30%的资金 投向A股，公募基金在消费板块的持仓比例也有所回升。 盈信量化（首源投资)端午节后A股市场或将面临 ...

Core Viewpoint - The Hong Kong pharmaceutical sector, particularly the innovative drug segment, is experiencing a significant surge, driven by recent high-profile collaborations and a shift towards international competitiveness among Chinese pharmaceutical companies [1][11]. Group 1: Innovative Drug Collaborations - Pfizer's collaboration with 3SBio involves a record-breaking upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, boosting confidence in the international capabilities of Chinese innovative drugs [1][5]. - Other notable collaborations include a $200 million upfront payment from United Pharmaceuticals to Novo Nordisk and a $175 million upfront payment from Hengrui Medicine to Merck, indicating a trend of increasing international partnerships [5]. - The average price-to-earnings (P/E) ratio for the Hong Kong pharmaceutical sector is currently at 15 times, significantly lower than the 24 times for both A-shares and U.S. stocks, suggesting a strong value proposition for investors [7]. Group 2: Technological Advancements - Chinese pharmaceutical companies are transitioning from "generic followers" to "innovation leaders," with R&D costs being only one-third of those in the U.S. and clinical trial durations reduced by 30% [1][2]. - Companies like Decipher Biosciences and Kintor Pharmaceutical are leveraging AI to enhance drug development efficiency, with significant improvements in response rates for clinical trials [1][2]. Group 3: Upcoming ASCO Conference - The 2025 ASCO Annual Meeting, scheduled for May 30 to June 3, will feature over 500 oral presentations and 2,700 poster presentations, with 71 original research projects from Chinese scholars, potentially leading to further stock price increases for involved companies [3][4]. Group 4: Market Dynamics and Valuation - The Hong Kong healthcare index has seen a nearly 20% increase prior to the announcement of 3SBio's contract, with a subsequent 4% rise following the news, indicating strong market interest [1]. - The current valuation levels are at historical lows, with some stocks trading below their net asset values, providing a significant safety margin for investors [7][8]. Group 5: Policy and Market Support - Recent policy changes have reduced pressures from centralized procurement, allowing innovative drugs to enter insurance coverage more rapidly, which is expected to enhance profitability for companies with genuine innovation capabilities [9]. - The government's support for biopharmaceuticals and the anticipated release of a new innovative drug directory could unlock over 300 billion yuan in market space, benefiting leading therapies like BeiGene's PD-1 inhibitors [9]. Group 6: Investment Trends - There has been a notable increase in capital inflow into the Hong Kong pharmaceutical sector, with net inflows into innovative drug ETFs exceeding 5 billion yuan since the second quarter [10]. - Active pharmaceutical funds are increasing their holdings in Hong Kong stocks, reflecting a growing confidence in the sector's potential for recovery and growth [10][11].

陈茂波在5月18日发布的文章中指出，今年以来，港股反复向好。恒生指数周五（5月16日）收报23345 点，累计升幅约16%，跑赢其他主要市场。大市交投亦有所增加，以4月份为例，平均每日成交超过 2,700亿元，较去年同期上升1.4倍。 在市场看来，在国内利率进入下行周期、资产配置重心逐步从增长转向回报的背景下，红利资产受到市 场较高关注。国信证券研报指出，尤其是在港股市场整体估值处于历史低位、企业派息意愿持续增强、 政策支持资本市场长期资金入市的环境中，港股通红利指数逐渐成为投资者配置高现金流、低波动品种 的重要工具。 财通证券研报认为，今年以来A股龙头公司赴港上市，受包括外资在内的投资者青睐，宁德时代当前H 股较A股溢价约10%，反映国内优质资产正受到全球投资者认可。后续有待在港交所上市的A股公司可 能受港股带动，享受估值修复红利。（闻辉） 【环球网财经综合报道】5月25日，香港财政司司长陈茂波发文透露，今年以来，香港新股集资额超过 760亿港元，较去年同期增加超过七倍，并已达到去年全年新股集资总额接近九成。 过去一周香港新股市场迎来了今年来全球最大宗的新股上市。5月20日，宁德时代在港交所上市。陈茂 波此 ...

Investment Rating - The industry rating is "Recommended" [4] Core Insights - The report highlights that Tmall and Taobao platforms experienced negative growth in various categories in April 2025, with the highest growth seen in Jin Hong Group [7] - Deckers reported a 16.3% revenue increase to $4.986 billion for FY2025, with operating profit rising by 27.1% to $1.179 billion, and a gross margin increase of 2.3 percentage points to 57.9% [15] - VF Corporation's revenue decreased by 4% to $9.504 billion for FY2025, with a net loss of $190 million, although the loss narrowed compared to the previous year [16] Summary by Sections Company Performance - Tmall and Taobao platforms saw negative growth across categories in April 2025, with Jin Hong Group showing the highest growth [7] - Deckers' FY2025 revenue grew by 16.3% to $4.986 billion, with operating profit increasing by 27.1% to $1.179 billion, and a gross margin of 57.9% [15] - VF Corporation's revenue fell by 4% to $9.504 billion, with a net loss of $190 million, but the loss was less than the previous year [16] - Amphenol's Q1 2025 revenue was $1.473 billion, with a net profit increase of 2539.22% [17] Market Trends - The textile and apparel industry saw a decline in stock performance, with the SW textile and apparel sector down 1.31% [20] - The cotton price index in China increased by 0.29% as of May 23, 2025, while the medium import cotton price index rose by 1.06% [30] - The USDA forecasts a 2.7% decrease in global cotton production for the 2025/2026 season [40] Investment Recommendations - The report suggests short-term recommendations for companies with high U.S. revenue exposure and significant prior declines, while mid-term recommendations focus on companies with high overseas exposure [18][19] - Long-term recommendations include companies with growth potential, such as Zhejiang Natural and Kai Run Co., which have favorable market positions [19]